Lataa...
Emerging agents and regimens for multiple myeloma
The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents a...
Tallennettuna:
| Julkaisussa: | J Hematol Oncol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7654052/ https://ncbi.nlm.nih.gov/pubmed/33168044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00980-5 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|